Preventive Cardiology focuses on identifying, modifying and managing cardiovascular risk factors to reduce the incidence of heart disease, stroke and metabolic disorders. As global cardiovascular burden continues to rise, clinicians increasingly seek structured frameworks and evidence-based strategies through expert-led cardiology conference sessions that cover risk assessment tools, lifestyle interventions, lipid management, hypertension control and long-term preventive pathways. Prevention remains the cornerstone of public health and clinical cardiology, making it essential for clinicians to develop strong competencies in early diagnosis, behavioural guidance and targeted medical therapy. Because this field aligns closely with cardiovascular risk reduction, this session provides practical and comprehensive insights into preventing disease across diverse populations.

This description begins with understanding major modifiable risk factors, including hypertension, diabetes, dyslipidemia, obesity, smoking and sedentary behaviour. Participants explore epidemiological patterns, population-level screening guidelines and structured clinical evaluation methods. The session explains the importance of ASCVD risk scoring, coronary calcium scoring, biomarker screening and genetic predisposition tools in identifying high-risk individuals early.

Lifestyle intervention plays a critical role in preventive cardiology. The session examines dietary patterns such as Mediterranean, DASH and plant-focused diets, discussing their impact on lipid profiles, blood pressure and inflammation. Exercise recommendations, including targeted aerobic and resistance training, help clinicians guide patients in developing sustainable routines. Additional counselling topics include weight reduction, stress management and smoking cessation strategies supported by behavioural therapy.

Medical therapy forms a major component of cardiovascular prevention. Participants learn to select appropriate lipid-lowering agents—including statins, ezetimibe and PCSK9 inhibitors—based on risk category and treatment goals. Hypertension management is covered extensively, focusing on combination therapy, diuretics, ACE inhibitors, ARBs and calcium-channel blockers. Diabetes therapy includes SGLT2 inhibitors and GLP-1 analogues, which offer cardioprotective benefits.

Preventive cardiology also emphasises special populations such as women, young adults, older adults and individuals with familial hypercholesterolemia. Clinicians explore genetic influences, sex-specific risk factors and early-life prevention frameworks that reduce long-term disease burden. The session also highlights the importance of psychosocial influences, environmental exposures and socioeconomic determinants of cardiovascular outcomes.

Future directions include personalised risk prediction models, digital health monitoring, remote prevention programmes, AI-assisted risk stratification and genomic-guided therapy selection. Participants leave with a structured blueprint for delivering proactive, patient-centred cardiovascular prevention.